A Preliminary Study Of The Expression Of Endoglin In Epithelial Ovarian Neoplasms

In current incidence of ovarian malignant tumor accounts for 2.4-5.6% of female common malignant tumor, becoming the first mortality of female proceating malignant tumor. In clinic 70% patients are found to be terminal disease period when they see a docter and mortality in 5 years is incredibly 70%, in which ovarian carcinoma account for around 90%.The existence in 5 years of cured early ovarian carcinoma patients is about 75%, obviously higher than terminal patients.So ovarian carcinoma early diagnosis is definitely the key to improve the pateints' 5- year existence and decrease mortality.Tumor angiogenesis is recent research hot topic.The neonatal vessel not only provide nutrition and oxygen needed by tumor cell, but also help tumor cell enter into blood circulation and lymphatic vessel to spread into all organs.To research the tumor angiogenesis can help deeply understand tumor occurrence, development and transferrence machnism. So far, the research abroad about ovarian carcinoma angiogenesis focus mainly on adjustive factor and the endothelial cell correlative antigen. The latter include CD34, CD31, von Willebrand factor(vWF) etc.Endoglin is a new marker of endothelial cells and a component of TGF-p-receptor complex.lt has the same genetic structure as TGF-pIII receptor (TpR-III). It is a membrane combined glycoprotein existing in superficial cell membrane and it participates in angiogenesis. In angiogenic areas,such as healing wounds and tumors, its endothelial cells particularly high express Endoglin. Endoglin has a close relation with tumor angiogenesis. Recently it has been an important biological target molecule for tumor diagnosis and tumor-EC-directed therapies.Microvessel density(MVD) is the golden standard to evaluate tumor angiogenesis. The denser MVD is, the larger general vascular surface area is. Besides, tumor cell entrance into vessel or lymph system has more possibility.So the chance of metastasis and tissue aggression is more. And the tumor prognosis will be even worse.To evaluate the relationship between MVD for Endoglin and tumor clinicalclassification and tumor cellular differentiation degree,we stain the endothelial cells with CD34 and Endoglin monoclone antibody respectively, and count MVD. To research expression of Endoglin mRNA in epithelial ovarian neoplasms and relativity with epithelial ovarian neoplasms quality and clinical classification,this experiment adopted immunohistochemistry and half quantity RT-PCR method to examinate the expression of TGF-β1 and Endoglin in epithelial ovarian neoplasms. The results are as follows:1. Endoglin has a positive expression in epithelial ovarian neoplasms endothelial cells and has a high expression in the surface of of tumor, as a result of its expression rate is much higher than CD34. MVD for endoglin is better than that for CD34 in evaluation tumor angiogenesis.MVD results have close relation with tumor quality, clinical classification and tumor cellular differentiation degree.We recommend that MVD for Endoglin contact with ovarian carcinoma prognosis.2. Endoglin mRNA express in tissue of both ovarian cystadenoma and ovarian cyst adenocarcinoma.But the expression in ovarian carcinoma is much higher. It showed that on one hand, the endothial cells in ovarian carcinoma tissue is actively multiply. On the other hand, Endoglin can probably be a new marker of malignant tumor angiogenesis.3. TGF-pl positive expression has a declining trend with the progress of epithelial ovarian neoplasms clinic classification and more severe of malignant degree. It illustrated that together declining expression of ovarian carcinoma cell TGF-pl and increasing expression of tumor endothelial cells Endoglin lead to tumor endothelial cells continously multiple and promoting tumor development.The result of this research shows that Endoglin is obviously better than CD34,the traditional panendothelial marker, in evaluation tumor angiogenesis.Besides, it contact with ovarian carcinoma characteristics, clinic classification and tum...